Pancreatic Cancer Research

ResearcherHokkaido UniversityActive in the last 2 years

Naoya Sakamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0061-059X; OpenAlex author ID A5024713150. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
2
Collaborators
33
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 14

  1. A Case With Longitudinal Changes in Apolipoprotein A2 Isoform Indices Associated With CA19-9 and MRI Findings Until Pancreatic Cancer Development. Last author DOI 10.1111/jgh.70857↗
  2. Clinical significance of dispersion imaging by shear wave elastography in the treatment and diagnosis of pancreatic cancer. Last author DOI 10.1111/jgh.16143↗
  3. Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pa… Co-author DOI 10.3390/jcm12041596↗
  4. Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration-Derived Samples. Last author DOI 10.1097/mpa.0000000000002028↗
  5. Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan… Co-author DOI 10.1136/bmjopen-2021-048833↗
  6. A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). Co-author DOI 10.1002/onco.13838↗
  7. Trial protocol: a randomised controlled trial to verify the non-inferiority of a partially covered self-expandable metal stent to an uncovered self-expandable … Last author DOI 10.1136/bmjopen-2020-045698↗
  8. Synchronous multiple needle tract seedings of the gastric wall after EUS-guided fine-needle biopsy for pancreatic cancer. Last author DOI 10.1016/j.gie.2020.05.005↗
  9. Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer. Last author DOI 10.1097/md.0000000000022250↗
  10. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis. Last author DOI 10.1016/j.pan.2019.04.007↗
  11. Hepatobiliary and Pancreatic: Pancreatic cancer with elevated serum IgG4 level due to multiple myeloma mimicking localized autoimmune pancreatitis. Last author DOI 10.1111/jgh.14088↗
  12. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic … Co-author DOI 10.1097/mpa.0000000000000760↗
  13. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. Last author DOI 10.21037/jgo.2017.02.02↗
  14. Is intraductal papillary mucinous neoplasm of the pancreas just a precursor or identical with pancreatic ductal adenocarcinoma? Last author DOI 10.1038/ajg.2013.468↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masaki Kuwatani · 8 shared papers, 2014–2026 · strength 1.02
  2. Kazumichi Kawakubo · 8 shared papers, 2014–2026 · strength 1.02
  3. Yoshito Komatsu · 7 shared papers, 2017–2023 · strength 0.73
  4. Ryo Sugiura · 4 shared papers, 2018–2026 · strength 0.68
  5. Yasuyuki Kawamoto · 6 shared papers, 2017–2023 · strength 0.67
  6. Shintaro Nakano · 5 shared papers, 2020–2023 · strength 0.61
  7. Kazuaki Harada · 4 shared papers, 2021–2023 · strength 0.49
  8. Shin Kato · 4 shared papers, 2018–2023 · strength 0.47
  9. Ayumi Kashiro · 1 shared paper, 2026 · strength 0.33
  10. Kazufumi Honda · 1 shared paper, 2026 · strength 0.33
  11. Tetsuhito Muranaka · 3 shared papers, 2017–2023 · strength 0.32
  12. Yunosuke Takishin · 2 shared papers, 2022–2023 · strength 0.28
  13. Yuh Sakata · 2 shared papers, 2022–2023 · strength 0.26
  14. Hideyuki Hayashi · 2 shared papers, 2017–2021 · strength 0.17
  15. Shuhei Hayasaka · 1 shared paper, 2020 · strength 0.15
  16. Atsushi Satō · 1 shared paper, 2022 · strength 0.12
  17. Shinya Kajiura · 1 shared paper, 2022 · strength 0.12
  18. Makoto Yoshida · 1 shared paper, 2021 · strength 0.11
  19. Masahiro Itonaga · 1 shared paper, 2021 · strength 0.11
  20. Shinichi Hashimoto · 1 shared paper, 2021 · strength 0.11
  21. Hiroyuki Inoue · 1 shared paper, 2021 · strength 0.11
  22. Hirotoshi Ishiwatari · 1 shared paper, 2021 · strength 0.11
  23. Takuji Iwashita · 1 shared paper, 2021 · strength 0.11
  24. Akio Katanuma · 1 shared paper, 2021 · strength 0.11
  25. Yusuke Mizukami · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.